Progenics tanks after two trial deaths cast doubt on its lead program

Damian Garde

Two patients died of sepsis in a Phase II of Pharmaceuticals' in-development prostate cancer treatment, spurring concern that the drug is too toxic to merit further study and sending the biotech's shares down as much as 30%.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS